Moderna had high hopes for its first seasonal flu vaccine to enter the clinic, but, so far, the mRNA shot hasn't quite lived up to the hype. While the vaccine checked off two influenza A strains in a phase 3 trial, it struggled against two B strains in the same test and had a higher level of adverse events than an approved flu shot.
https://www.fiercebiotech.com/biotech/moderna-checks-few-boxes-phase-3-flu-shot-trial-misses-b-strains-and-safety
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$257.38 |
Change
8.990(3.62%) |
Mkt cap ! $124.6B | |||
| Open | High | Low | Value | Volume |
| $252.00 | $258.31 | $251.10 | $370.9M | 1.440M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 90 | $257.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $257.38 | 3331 | 1 |
View Market Depth
| Last trade - 16.11pm 18/07/2025 (20 minute delay) ? |
| CSL (ASX) Chart |